Micofenolato Mofetile Tillomed

Mycophenolate Mofetil, the active ingredient in Micofenolato Mofetile Tillomed, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat selected autoimmune disorders such as lupus nephritis, acting by inhibiting lymphocyte proliferation.

GNH USA supplies Micofenolato Mofetile Tillomed as a licensed, GDP‑compliant international pharmaceutical product, adhering to EU GMP standards and providing reliable supply to hospitals, transplant centres, and pharmacies across global markets through established distribution networks and regulatory support.

Mycophenolate Mofetil is used in immunosuppressive regimens to prevent rejection and to manage certain autoimmune kidney diseases.

- Renal transplant: helps prevent acute graft rejection. - Cardiac transplant: reduces the incidence of rejection episodes. - Lupus nephritis: improves renal function and slows disease progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, sometimes watery. - Headache: intermittent mild to moderate pain. - Infections (upper respiratory): increased susceptibility to colds and sinusitis.

Serious or Rare Side Effects: - Leukopenia: marked reduction in white blood cells. - Severe infections: opportunistic or systemic infections. - Hepatic toxicity: elevated liver enzymes or hepatitis.

Patients should be monitored closely for safety concerns.

- Monitor blood counts: regular CBC to detect leukopenia or anemia. - Monitor liver function: periodic LFTs for hepatic toxicity. - Avoid in pregnancy: teratogenic risk; pregnancy category X. - Use effective contraception: both male and female patients of reproductive potential. - Adjust dose in renal impairment: follow prescriber guidance for reduced clearance. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increased mycophenolate exposure. - Rifampin: reduces mycophenolate plasma levels. - Live vaccines: heightened risk of infection. - Cholestyramine: decreases oral absorption.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: potential for hyperkalemia when combined with renal impairment. - NSAIDs: may worsen renal function. - Antacids (e.g., aluminum hydroxide): can lower mycophenolate bioavailability.